Table 6.
Potential drug–drug interactions (pDDIs) among 111 * CKD patients according to demographic and clinical variables groups.
| Variable | Number | Median (25%–75% Percentile) |
p–Value 1 |
|---|---|---|---|
| Gender | 0.5768 2 | ||
| Female | 68 | 7 (2–12.7) | |
| Male | 43 | 7 (2–11) | |
| Age | 0.0191 | ||
| 30–60 | 11 | 2 (0–5) | |
| 61–70 | 8 | 3.5 (0.5–7.7) | |
| 71–80 | 44 | 8 (3.2–16) | |
| >80 | 48 | 8 (3–11) | |
| CKD stage ** | 0.4930 | ||
| G1 | 10 | 3.5 (0.7–12.7) | |
| G2 | 15 | 8 (3–12) | |
| G3a | 34 | 5 (1–9.2) | |
| G3b | 33 | 8 (3–13) | |
| G4 | 14 | 4 (3–13) | |
| G5 | 5 | 11 (4–17.5) | |
| Concomitant drugs | <0.0001 | ||
| ≤5 | 21 | 1 (0–2) | |
| 6–10 | 59 | 6 (4–9) | |
| 11–15 | 29 | 16 (11–20) | |
| >15 | 2 | 26 (16–36) | |
| Chronic comorbid disease | 0.0611 | ||
| 0 | 20 | 6.5 (3.2–11) | |
| 1 | 21 | 7 (2–12.5) | |
| 2 | 20 | 6.5 (3–10.7) | |
| 3 | 10 | 12 (7.2–20.5) | |
| 4 | 17 | 7 (1–17.5) | |
| ≥5 | 23 | 4 (1–7) |
* One patient had not taken any drugs; ** according to the classification of chronic kidney disease from Kidney Disease: Improving Global Outcomes (KDIGO); 1 ANOVA Kruskal–Wallis test; 2 Mann–Whitney t-test.